Humana Extends TailorCare Tie-Up to Enhance MA Member Health

Humana Inc. HUM recently solidified its partnership with TailorCare, a leading value-based specialty care provider for musculoskeletal (MSK) health, to serve Medicare Advantage (MA) members in Dallas and Denver. Starting in November 2025 in Dallas and in January 2026 in Denver, Humana MA members can avail TailorCare’s personalized, evidence-based MSK navigation and care coordination services. It already serves HUM members across Atlanta. 

TailorCare’s approach begins early in the care journey to prevent pain from progressing to invasive or avoidable treatments. Each Humana MA member referred to the program undergoes a structured evaluation with a licensed physical therapist. This assessment leads to a tailored care plan, which may encompass conservative therapy, in-person physical therapy, specialist referrals within the network, and self-care guidance at home.

As a result of the expanded tie-up, Humana members will also benefit from one of the most advanced home-based physical therapy programs in the country, offering more than 225 evidence-based clinical pathways with personalized exercise routines, certified health coaching for lifestyle support and sensor-free motion tracking technology for progress monitoring. 

The recent move also seems to be a time-opportune one since musculoskeletal disorders, including arthritis, osteoporosis and joint issues, affect a significant portion of the American population and lead to escalating healthcare costs.

Benefits of the Recent Move to Humana

Humana aims to improve health outcomes for its MA members suffering from joint, back and muscle conditions as a result of the expanded partnership, while reducing unnecessary procedures and high costs.

The beneficial nature of TailorCare services is likely to retain existing MA customers and attract new ones to opt for Humana’s healthcare plans. Increased plan adoption is expected to expand HUM’s MA membership base and bring higher premium revenues to the health insurer. Total MA membership came in at 5.8 million as of June 30, 2025. Overall premiums advanced 8.6% year over year in the first half of 2025.

HUM’s Share Price Performance & Zacks Rank

Shares of Humana have gained 8.3% in the past three months compared with the industry’s 3.5% growth. HUM currently carries a Zacks Rank #3 (Hold).

Stocks to Consider

Some better-ranked stocks in the Medical space are ANI Pharmaceuticals, Inc. ANIP, The Ensign Group, Inc. ENSG and Novartis AG NVS. While ANI Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Ensign Group and Novartis carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

ANI Pharmaceuticals’ earnings surpassed estimates in each of the last four quarters, the average surprise being 22.66%. The Zacks Consensus Estimate for ANIP’s 2025 earnings indicates a rise of 39.8% while the same for revenues implies an improvement of 36.9% from the respective year-earlier actuals. The consensus mark for ANIP’s earnings has moved 11% north in the past 60 days. 

The bottom line of Ensign Group outpaced estimates in each of the trailing four quarters, the average surprise being 1.85%. The Zacks Consensus Estimate for ENSG’s 2025 earnings indicates a rise of 16.2% while the same for revenues implies an improvement of 17.2% from the respective year-earlier actuals. The consensus mark for ENSG’s earnings has moved 1.3% north in the past 60 days.

Novartis’ earnings surpassed estimates in each of the last four quarters, the average surprise being 6.20%. The Zacks Consensus Estimate for NVS’ 2025 earnings indicates a rise of 15.2% while the consensus mark for revenues implies an improvement of 10.5% from the respective year-earlier actuals. The consensus mark for NVS’ earnings has moved 0.4% north in the past 60 days.

Shares of ANI Pharmaceuticals, Ensign Group and Novartis have gained 44.2%, 11.2% and 4.1%, respectively, in the past three months.   

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research